Comparison of the Dosimetric Influence of Applicator Displacement on 2D and 3D Brachytherapy for Cervical Cancer Treatment

Abstract

To compare the dosimetric influence of applicator displacement on two-dimensional brachytherapy (2D-BT) and three-dimensional brachytherapy (3D-BT) for cervical cancer. Nineteen patients who received computed tomography-guided tandem-and-ovoid (T&O) brachytherapy were retrospectively selected. Both 2D (point-based) and 3D (volume-based) plans with and without virtual applicator displacement in the 3 axes were created for each patient. Dose changes at point A, D 90 of the high-risk clinical target volume (HR-CTV) and intermediate-risk CTV (IR-CTV), and the D 0.1cc , D 1cc , D 2cc , and D 5cc of organs-at-risk (OARs) caused by applicator displacement were evaluated. Both 2D-BT and 3D-BT plans were sensitive to T&O applicator displacement. The D 90 of the CTV and the dose at point A were very sensitive to applicator displacement in the right–left direction ( X -axis). An applicator shift of >2 mm in the X -axis resulted in a change of >5% in the dose at point A and D 90 of HR-CTV and IR-CTV. In addition, the doses to the OARs were mostly affected by applicator displacement in the anterior–posterior direction ( Z -axis). A displacement of 10% for OARs. For both 2D-BT and 3D-BT plans, T&O displacement greater than ± 2 mm in the X -axis or T&O applicator displacement ± 1.5 mm in the Z -axis resulted in significant dose changes to the tumor and OARs. In comparison with 3D-BT plans, 2D-BT plans delivered a higher dose to the tumor, and the OARs received more undesirable doses when applicator displacement occurred. The influence of applicator displacement on the doses to the tumor and OARs differed between 2D-BT and 3D-BT. Physicians should take individual patient differences into account when selecting a brachytherapy plan to mitigate the influence of applicator displacement.